Wedbush Securities Inc. Has $521,000 Position in Omeros Co. (OMER)
Wedbush Securities Inc. lowered its holdings in Omeros Co. (NASDAQ:OMER) by 45.3% in the third quarter, Holdings Channel reports. The firm owned 21,330 shares of the biopharmaceutical company’s stock after selling 17,675 shares during the period. Wedbush Securities Inc.’s holdings in Omeros were worth $521,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Millennium Management LLC bought a new position in Omeros during the 2nd quarter worth approximately $8,513,000. Foresite Capital Management IV LLC bought a new position in Omeros during the 3rd quarter worth approximately $8,690,000. Ingalls & Snyder LLC lifted its holdings in Omeros by 1.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock worth $101,829,000 after buying an additional 70,625 shares during the last quarter. Alps Advisors Inc. bought a new position in Omeros during the 2nd quarter worth approximately $1,271,000. Finally, Cpwm LLC lifted its holdings in Omeros by 5.0% during the 2nd quarter. Cpwm LLC now owns 1,074,543 shares of the biopharmaceutical company’s stock worth $19,492,000 after buying an additional 51,015 shares during the last quarter. 47.50% of the stock is owned by hedge funds and other institutional investors.
Shares of Omeros stock opened at $14.02 on Friday. The company has a market cap of $699.85 million, a PE ratio of -17.75 and a beta of 3.90. Omeros Co. has a twelve month low of $8.36 and a twelve month high of $27.00.
OMER has been the topic of a number of research analyst reports. HC Wainwright set a $34.00 target price on Omeros and gave the stock a “buy” rating in a report on Wednesday, August 29th. BidaskClub raised Omeros from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 17th. Maxim Group set a $32.00 target price on Omeros and gave the stock a “buy” rating in a report on Thursday. ValuEngine downgraded Omeros from a “buy” rating to a “hold” rating in a report on Friday, August 10th. Finally, Zacks Investment Research downgraded Omeros from a “hold” rating to a “sell” rating in a report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Omeros currently has a consensus rating of “Hold” and an average target price of $27.56.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: Moving Average – How it Helps Investors in Stock Selection
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.